Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 7.3% – Here’s What Happened

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)’s share price was down 7.3% during trading on Friday . The company traded as low as $3.88 and last traded at $3.9850. Approximately 7,668,251 shares traded hands during mid-day trading, a decline of 49% from the average daily volume of 15,027,618 shares. The stock had previously closed at $4.30.

Iovance Biotherapeutics News Summary

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Zacks Research raised its Q1 2028 EPS estimate for Iovance Biotherapeutics to ($0.08) from ($0.09), implying slightly better expected profitability. Iovance Biotherapeutics analyst estimate update
• Positive Sentiment: Analysts also increased estimates for Q2 2027 to ($0.11) from ($0.13) and Q1 2027 to ($0.13) from ($0.16), suggesting a somewhat improved earnings trajectory. Iovance Biotherapeutics analyst estimate update
• Positive Sentiment: A Zacks article said Iovance’s commercial momentum and expanding Amtagvi pipeline make it look better positioned than peer Agenus, which may reinforce a constructive view on the stock. Zacks article on Iovance versus Agenus
• Neutral Sentiment: Zacks Research trimmed some longer-dated estimates, including FY2026 to ($0.71) from ($0.69), Q3 2026 to ($0.17) from ($0.16), and Q4 2026 to ($0.17) from ($0.14), indicating the company is still expected to remain unprofitable for now. Iovance Biotherapeutics estimate revisions
• Neutral Sentiment: The company’s recent earnings backdrop remains mixed: revenue growth has been strong year over year, but the last reported quarter still missed revenue expectations, keeping investors focused on execution.

Analysts Set New Price Targets

A number of equities analysts recently commented on IOVA shares. Barclays raised their price objective on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Monday, April 6th. Wall Street Zen raised shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Chardan Capital decreased their price objective on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, The Goldman Sachs Group reaffirmed a “sell” rating and issued a $2.00 price objective on shares of Iovance Biotherapeutics in a research note on Thursday, February 5th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.43.

Iovance Biotherapeutics Trading Down 6.6%

The business’s fifty day moving average price is $3.65 and its 200 day moving average price is $3.11. The company has a market capitalization of $1.79 billion, a P/E ratio of -4.24 and a beta of 0.69.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.19). Iovance Biotherapeutics had a negative net margin of 123.92% and a negative return on equity of 50.17%. The firm had revenue of $71.43 million during the quarter, compared to the consensus estimate of $77.84 million. During the same period last year, the firm posted ($0.36) EPS. The firm’s quarterly revenue was up 44.9% on a year-over-year basis. Equities research analysts anticipate that Iovance Biotherapeutics, Inc. will post -0.63 EPS for the current year.

Institutional Investors Weigh In On Iovance Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Iovance Biotherapeutics by 13.1% during the fourth quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock worth $74,275,000 after purchasing an additional 3,148,096 shares in the last quarter. State Street Corp boosted its position in shares of Iovance Biotherapeutics by 51.5% during the fourth quarter. State Street Corp now owns 20,161,445 shares of the biotechnology company’s stock worth $55,041,000 after purchasing an additional 6,851,486 shares in the last quarter. Invenomic Capital Management LP boosted its position in shares of Iovance Biotherapeutics by 13.5% during the fourth quarter. Invenomic Capital Management LP now owns 11,959,505 shares of the biotechnology company’s stock worth $32,649,000 after purchasing an additional 1,417,897 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Iovance Biotherapeutics by 30.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 8,607,564 shares of the biotechnology company’s stock worth $23,499,000 after purchasing an additional 2,032,062 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Iovance Biotherapeutics by 16.4% during the fourth quarter. Geode Capital Management LLC now owns 7,991,640 shares of the biotechnology company’s stock worth $21,821,000 after purchasing an additional 1,123,337 shares in the last quarter. 77.03% of the stock is owned by institutional investors.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.